Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib combined with chemotherapy for recurrent ovarian cancer
ChiCTR1800019210Phase 4Recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Nov 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in ovarian cancer, sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoint: progression-free survival. Started Nov 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ChiCTR1800019210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019210.